Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts

Constance Delaugerre; Lambert Assoumou; Sarah Maylin; Marine Minier; Audrey Gabassi; Michèle Genin; Lydie Beniguel; Jade Ghosn; Xavier de Lamballerie; Mayssam El Mouhebb; Dominique Costagliola; Fabrice Carrat; Jean Michel Molina; PREVENIR and SAPRIS-Sero Study Groups

doi:10.1093/ofid/ofac188

Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts

Open Forum Infect Dis. 2022 Apr 12;9(7):ofac188. doi: 10.1093/ofid/ofac188. eCollection 2022 Jul.

Affiliations

¹ Service de Virologie, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
² Sorbonne Université, Inserm, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
³ Service de Maladies infectieuses, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Infection, Antimicrobials, Modelling, Evolution, Inserm, Université mixte de recherche 1137, Université de Paris, Paris, France.
⁴ Unité des Virus Emergents, Université Aix Marseille, Institut de recherche pour le développement 190, Inserm U1207, Marseille, France.
⁵ Université de Paris, Inserm, U944, Paris, France.

Abstract

The potential preventive efficacy of tenofovir/emtricitabine on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was assessed in human immunodeficiency virus preexposure prophylaxis (PrEP) users. Prevalence of SARS-CoV-2 immunoglobulin G between May and October 2020 was similar in PrEP users and in a matched population-based cohort, suggesting that tenofovir/emtricitabine has no role in reducing the risk of SARS-CoV-2 acquisition.

Keywords: HIV; PrEP; SARS-CoV-2.